Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 11, 2001, Pages 596-603

  Fox Geiman, Mary P ^a   Fisher, Susan G ^a   Kiley, Karen ^a   Fletcher Gonzalez, Donna ^a   Porter, Nancy ^a   Stiff, Patrick ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiemetics; Granisetron; High dose chemotherapy; Ondansetron; Stem cell transplantation

Indexed keywords

ANTIEMETIC AGENT; BENZODIAZEPINE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GRANISETRON; IFOSFAMIDE; LORAZEPAM; MELPHALAN; MITOXANTRONE; ONDANSETRON; PACLITAXEL; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; THIOTEPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; POPULATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STEM CELL TRANSPLANTATION; TABLET; WHOLE BODY RADIATION;

EID: 0035195041     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11760147     Document Type: Article

References (45)

1. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: A multicentre double-blind, randomized, parallel-group study
2. A double-blind randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference
3. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: Results of a prospective randomized trial
4. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatin-induced emesis: An open randomized cross-over study
5. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis
6. Ondansetron versus granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis
7. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: A randomized controlled trial
8. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
9. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis
10. Continuous infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy
11. A prospective randomized trial of the antiemetic efficacy of ondansetron and granisetron during bone marrow transplantation
12. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant
13. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation
14. Neuropharmacology of emesis and its relevance to anti-emetic therapy: Consensus and controversies
15. Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs
16. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatin-based chemotherapy: Effects of antiemetics
17. Plasma chromagranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies
18. On the mechanism of radiation-induced emesis: The role of serotonin
19. Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis
20. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly
21. Methodology of antiemetic trials: A review
22. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
23. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation
24. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
25. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: Toxicity and antitumor activity in 26 patients with poor-risk malignancies
26. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data
27. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study
28. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer
29. High dose carboplatin and etoposide for salvage chemotherapy of germ cell tumors
30. A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: Analysis of risk factors for clinical outcome
31. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors
32. Marrow transplantation for acute non-lymphoblastic leukemia in first remission: Toxicity and long-term follow-up of patients conditioned with single-dose or fractionated total body irradiation
33. Proposal for classifying the acute emetogenicity of cancer chemotherapy
34. Protection from nausea and vomiting in cisplatin-treated patients: High-dose metoclopramide combined with methylprednisolone vs. metoclopramide combined with dexamethasone and diphenhydramine: A study for Clinical Research
35. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation
36. Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant
37. The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and lorazepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support
38. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: A prospective randomized study
39. 3 receptor antagonists the same?
40. A randomized trial of once vs. twice daily administration of intravenous granisetron with dexamethasone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin
41. Mechanisms by which cancer chemotherapy drugs induce emesis
42. Randomized trial for the prevention of delayed emesis in patients receiving high-dose cisplatin
43. Antiemetic research: A look to the future
44. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist